Description
OVERVIEWProduct overview
Tirzepatide is a 39-amino-acid synthetic peptide engineered to activate both the GIP and GLP-1 receptors from a single sequence.
Research interest centres on whether dual incretin engagement produces different metabolic endpoints than GLP-1 agonism alone, and the compound is frequently used as a comparison arm alongside semaglutide.
All published work is preclinical or investigational. This material is supplied as a laboratory reference compound and is not authorised as a medicine in Ireland, the UK or the EU.
SUPPLY IN IRELANDTirzepatide Ireland — supplied to research laboratories
Research groups across Ireland buy Tirzepatide from Kensington Laboratories as a lyophilised Tirzepatide peptide, released only against a batch-matched certificate of analysis. Every vial of high purity Tirzepatide is verified by HPLC and LC-MS before it leaves the facility, so laboratories ordering Tirzepatide in Ireland receive material with documented purity and identity.
Laboratory Tirzepatide is packed for controlled storage and sent by tracked delivery in 3–5 days to Dublin, Cork, Galway, Limerick and the rest of Ireland. Delivery costs €9.90 per order. Teams planning Tirzepatide research can review the specifications, certificate of analysis and reference list on this page before ordering.
Institutions searching for Tirzepatide peptide suppliers in Ireland typically compare purity, batch documentation and delivery times. Each of those is published here: a 99% HPLC purity specification, a certificate matched to the batch code on your vial, and tracked delivery in 3–5 days.
Tirzepatide is supplied strictly for laboratory research use only. It is not a medicine and is not for human or veterinary consumption.
SPECIFICATIONSProduct specifications
- Purity: ≥ 99% (HPLC)
- Appearance: White lyophilised powder
- Quantity: 10 mg or 5 mg or 15 mg or 30 mg or 50 mg per vial
- CAS number: 2023788-19-2
- Peptide class: Synthetic dual GIP and GLP-1 receptor agonist peptide
- Also known as: LY3298176, dual GIP/GLP-1 agonist
- Solubility: Soluble in bacteriostatic or sterile water
- Storage temperature: Store at 2–8°C; long-term −20°C, protected from light
- Shelf life: 24 months lyophilised; 30 days reconstituted at 2–8°C
- Manufacturing standard: ISO 9001 facility, GMP-aligned solid-phase synthesis
- Batch information: Batch number and expiry printed on every vial label
RESEARCHResearch overview
The following summary is provided for educational and scientific context only. It describes what has been observed in published laboratory and animal studies and does not represent established clinical outcomes, medical advice or a claim of efficacy in humans.
Background
Tirzepatide is a 39-amino-acid synthetic peptide engineered to activate both the GIP and GLP-1 receptors from a single sequence.
Research interest centres on whether dual incretin engagement produces different metabolic endpoints than GLP-1 agonism alone, and the compound is frequently used as a comparison arm alongside semaglutide.
All published work is preclinical or investigational. This material is supplied as a laboratory reference compound and is not authorised as a medicine in Ireland, the UK or the EU.
Current research areas
Published investigation clusters around a small number of biological themes. Each remains experimental and none has been established as a therapeutic effect in humans.
- Comparative GIP and GLP-1 receptor pharmacology
- Insulin sensitivity and lipid handling in rodent models
- Adipose tissue signalling endpoints
- Head-to-head comparison with single-receptor agonists
Scientific context and proposed mechanisms
Authors describe biased agonism at the GLP-1 receptor combined with full GIP receptor activity, with a C20 fatty di-acid moiety conferring albumin binding and a long circulating half-life in animal studies.
Interpreting the evidence
Most published work in this area uses cell culture or rodent models with small group sizes and short observation windows. Independent replication varies considerably between compounds, and results are sensitive to species, route, dose and endpoint.
There is no regulatory-approved human protocol for this compound. Any laboratory protocol should be defined by the model under study, institutional ethical approval, appropriate controls and predefined endpoints.
References
CERTIFICATE OF ANALYSISIndependent batch testing
Every released batch is independently tested. Match the batch number on the vial to the certificate published online.
- Batch number
- KL-TIRZEPATID-2409A
- Testing laboratory
- Janoshik Analytical, s.r.o.
- Date tested
- 12 August 2026
- Reported purity
- 99.78%
- Method
- RP-HPLC with UV detection at 214 nm, confirmed by LC-MS
The independent result for this batch is summarised above. Contact the laboratory team if you need the full report for this batch.
